➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKesson
Medtronic
Merck
Express Scripts

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 9,943,649

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,943,649
Title:Automatic injection device
Abstract: Automatic injection device includes a housing, a syringe, a plunger, and a syringe carrier. The housing includes a barrel between a first end and a second end. The barrel includes an elongated window to allow viewing of contents inside the housing. The syringe is disposed within the housing and has a reservoir. The plunger is at least partially disposed within the syringe and includes a visual indicator. The syringe carrier is disposed within the housing and configured to contain the syringe and displace the syringe within the housing between a first position and a second position. The syringe carrier can be substantially transparent. The syringe carrier can have first and second legs and an extension disposed therebetween, and at least a portion of the extension can be configured to align with the window and the reservoir when the syringe carrier is in the first position.
Inventor(s): Shang; Sherwin (Vernon Hills, IL), Tsvirko; Eduard (Arlington Heights, IL), Chim; Edwin (Vernon Hills, IL), Somashekar; Shubha Chethan (Waukegan, IL), Ozdaryal; Esra (Deerfield, IL), Julian; Joseph F. (Libertyville, IL), Li; Chuan (Deerfield, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/220,782
Patent Claims:see list of patent claims

Details for Patent 9,943,649

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial AbbVie Inc. (North Chicago, IL) 2031-09-22 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial AbbVie Inc. (North Chicago, IL) 2031-09-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Moodys
Express Scripts
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.